CYP1A2 INDUCER

Status - Drug Discovery Phase: Hit on the Lead Compound & Patent Approved.  Project has strong probability (known mechanism, smaller risk for side effects) to progress to Phase I FDA clinical trials.

Drug Platform Profile

Seeking: Funded Co-Development, Out-Licensing Opportunities & Series A investors.

Linnet BioPharmaceuticals has granted and pending patents for a unique drug platform creating first-in-class therapeutics to treat caffeine-induced insomnia and caffeine-induced anxiety with upside potential as a precursor to cardiac stress testing.  The plant based parent, rutacarpine, is known to induce CYP1A2 that increases caffeine metabolism effectively reducing its effects.  

  • Large global unmet need for caffeine over-consumption treatment

  • Peak sales potential $400-500MM

  • Non-CNS mechanism and zero systemic absorption avoids common side effects that plague the CNS drug class.

  • Potential for orphan drug classification as an antidote to caffeine and theophylline overdose or other xanthine-derivative induced toxicities

We are seeking parties able to carry the patented series through drug discovery, preclinical and clinical phases I and II.

Linnet Biopharamceuticals Inc was founded in 2010, by Drs. Stan and Tim Linnet  who recognized the market need for a sleep aid that allowed consumers to counter their caffeine consumption.

Caffeine’s stimulant effects are sought during waking hours but are disruptive during sleeping hours and can cause stress. The company’s products improve the consumer’s lifestyle by allowing the benefits of caffeine during the day while allowing a restful sleep at bedtime.  Stress and anxiety are relieved through improved sleep and decreased CNS stimulation.